MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer. The main question it aims to answer is: Is microboost SBRT with whole gland de-escalation both safe and effective in managing patients with low to intermediate-risk prostate cancer while maintaining acceptable toxicity levels? All patients will receive microboost SBRT at a dose of 45 Gy delivered in 5 fractions in up to 4 MRI-defined lesions. Patients (Arm 1) with highest grade disease in the microboost target l

Trial Details

NCT ID
NCT07644598
Phase
PHASE2
Sponsor
Georgetown University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Microboost SBRT
  • Whole gland de-escalation 30 Gy
  • Whole gland de-escalation 35 Gy
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Patients age 18 or older.
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Patients with histologically confirmed adenocarcinoma of the prostate who have not received prior pelvic radiation therapy or prostatectomy.
  • Patients with low to intermediate risk group defined by the NCCN (National Comprehensive Cancer Network) guidelines as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →